The deal will see the multinational drug company manufacture the active pharmaceutical ingredient (API) for DBV’s allergy treatment Viaskin from its site at Aramon, France.
Chairman and CEO of DBV, Dr. Pierre-Henri Benhamou, said “the extraction and protein expertise of Sanofi” would benefit DBV and expressed this would be a long term collaboration with Saniofi securing “API procurement in the years to come.”
Sanofi will act as a contract manufacturer (CMO) and will scale-up and validate the API in order to supply full commercial scale for DBV.
Though the Aramon site is fully accredited by the US Food and Drug Administration (FDA), Viaskin – which uses plant and protein extracts in order to provide a treatment to allegies such as peanuts and milk – is at present not approved for sale in the US.